EGFR and neoplasm: CTCs were identified in 15 samples from 13 patients with mutations consistent with those found in the matching tumour tissue. EGFR T790 mutation was detected in both relapsed tissue and CTCs from 2 patients where an initial tumour biopsy did not present this mutation. Analysis of EMT signature of individual pretreatment CTCs is able to predict drug responsiveness in patients.